A Phase 4 interventional study of Atorvastatin in Major Coronary Event, Cerebrovascular Accident and Coronary Artery Bypass Graft, sponsored by Pfizer. Completed at 135 sites in United Kingdom. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-05-10.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing atorvastatin in Stroke — 4 open to participants now, 4 under way, 2 of them phase 3. Atorvastatin · Stroke.
Among the 17 studies testing atorvastatin in Stroke, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 1997, is one of 7 in phase 4, and was the 3rd registered.
8,277 studies on the registry are indexed under Stroke; 2,067 are open to participants now.
Browse Stroke studies →4 of the 17 studies testing atorvastatin in Stroke are open now, in 2 countries. Recruiting first, the newest first:
Duan Chuanzhi · Sites in China
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–60
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 7
First in 1997; this study’s year is marked. 1 started in 1997.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,800 is above the median of 49 across 6,043 interventional studies indexed under Stroke.
Median enrollment 365 across the 16 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
12 studies in Stroke by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 12 studies in Stroke by Pfizer, this one is the only one that started in 1997, is one of 2 in phase 4, and was the 2nd registered.
Pfizer’s Stroke studies by the year they started, since 1997.
1 of the studies testing atorvastatin in Stroke that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07875335The First Affiliated Hospital with Nanjing Medical UniversityFufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya Disease | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing atorvastatin in Stroke, from their registry updates:
Among Pfizer’s 12 in Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have a documented history of at least one of the following:
Exclusion Criteria:
Time from randomization to the occurrence of a primary clinical endpoint
i.e. major coronary event or CABG or other coronary revascularization procedure
or unstable angina or resuscitated cardiac arrest or stroke.
The incidence rate of a primary clinical and endpoint; the time from randomization
to the occurrence of and the incidence rate of other parameters e.g. total
mortality, any cardiovascular event, new PVD etc. and the percent change from
baseline in various lipid and lipoprotein parameters.
Showing the first 100 of 135 sites. Choose a country and city above to see the rest.
The record gives a start of Jan 1997 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin